1. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

2. Patient Presentation

3. On Exam

4. Patient Follow-Up 8 Weeks

5. Case Questions

6. Estimated Frequency of Individuals With Familial Hypercholesterolemia

7. Problems in Identifying FH Patients

8. Statin Myopathy is a Common Challenge in Lipid Management

9. Statins and New-Onset Type 2 Diabetes Facts and Clinical Implications

10. Case Questions

11. Therapy for Statin Intolerance

12. ODYSSEY FH I + II Alirocumab Significantly Reduced LDL-C From Baseline to Week 24 vs Placebo

13. Safety Analysis (Pooled Data From FH I and FH II)

14. ODYSSEY Combo Alirocumab Significantly Reduced LDL-C From Baseline to Week 25 vs Ezetimibe

15. ODYSSEY LONG TERM Alirocumab Maintained Consistent LDL-C Reduction Over 52 Weeks

16. Adverse Events of Special Interest

17. Post-hoc Adjudicated Cardiovascular Events*

18. Abbreviations

19. Abbreviations (cont)

20. Abbreviations (cont)

21. References

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)